Overview
DWTX market data
Price History
DWTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.84 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.28 – $9.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $61.5M · P/B 1.65.
Company News
Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) EstimateBenzinga · Aug 13, 2026, 12:54 PM
8-K filing — Dogwood Therapeutics, Inc. (DWTX)SEC EDGAR · Aug 13, 2026, 12:50 PM
Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of HalneuronBenzinga · Jul 20, 2026, 12:34 PM
Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension TrialBenzinga · May 18, 2026, 12:50 PM